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Objective: The aim of this study was to identify the preferences for whole genome sequencing 
(WGS) tests without genetic counseling.
Methods: A discrete choice experiment was conducted where participants chose between 
two hypothetical alternatives consisting of the following attributes: test accuracy, test costs, 
identified diseases, probability of disease occurrence, and data access. People from the general 
German population aged ≥18 years were eligible to participate in the survey. We estimated 
generalized linear mixed effects models, latent class mixed-logit models, and the marginal 
willingness to pay.
Results: Three hundred and one participants were included in the final analysis. Overall, the 
most favored WGS testing attributes were 95% test accuracy, report of severe hereditary diseases 
and 40% probability of disease development, test costs of €1,000, and access to test results 
for researchers. Subgroup analysis, however, showed differences in these preferences between 
males and females. For example, males preferred reporting of results at a 10% probability of 
disease development and females preferred reporting of results at a 40% probability. The test 
cost, participant’s educational level, and access to data influenced the willingness to participate 
in WGS testing in reality.
Conclusion: The German general population was aware of the importance of genetic research 
and preferred to provide their own genetic data for researchers. However, among others, the 
reporting of results with a comparatively relatively low probability of disease development at 
a level of 40%, and the test accuracy of 95% had a high preference. This shows that the results 
and consequences of WGS testing without genetic counseling are hard to assess for individu-
als. Therefore, WGS testing should be supported by qualified genetic counseling, where the 
attributes and consequences are explained.
Keywords: whole genome sequencing, discrete choice experiment, genetic testing, preferences, 
willingness to pay, latent class model
Introduction
In the past 10 years, significant progress has been achieved in the fields of genomics 
and genetics.1 The usage of genetic information has steadily increased in medical 
research, diagnosis, and therapy. Essential drivers for this development are as follows: 
1) technological progress such as next-generation sequencing (NGS) technologies, 
2) the reduction in costs of sequencing,2 3) growth in population and clinical-based 
biobanks,3 and 4) the increasing knowledge of genotype–phenotype correlations based 
on genome-wide association studies (GWAS).4
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Genetic information is essential for personalized 
medicine. This knowledge enables preventive health care 
management as well as the administration of personalized 
and targeted therapies based on an individual’s genetic char-
acterization.5 The scope of analysis (gene, panel, exome, or 
whole genome sequencing [WGS]) and the amount of genetic 
data vary with the aim of the investigation. WGS provides an 
opportunity to identify almost all disease-causing  variants.6 
For this reason, WGS seems to be the most appropriate 
method for comprehensive predictive analysis.
In recent years, the suitability of WGS as a screening tool 
has been discussed, especially in newborn7 or population-
based screening.8 Notwithstanding the economic (eg, clinical 
utility),9 ethical, and legal debates (eg, information of self-
determination),10 the detection of rare and/or highly penetrant 
diseases before the onset of disease may have considerable 
advantages. For example, previous surveys indicated that 
early diagnosis of cystic fibrosis11 or Lynch syndrome12 is 
beneficial for treatment, and the knowledge of predisposi-
tions to oncological and cardiovascular diseases can be useful 
for prevention. Knowledge of a BRCA I/BRCA II mutation 
allows the development of a prevention strategy including 
regular checkups and mastectomy.13
Several studies showed that people are interested in 
genetic testing.14–16 They want to take a proactive role in 
preventive health care management for themselves as well 
as for their family members.17 However, WGS testing aimed 
at primary prevention without a suspected disease is gener-
ally not covered by health insurance plans (eg, in Germany). 
Genetic analysis distributed via the Internet is a less expen-
sive alternative than the conventional market.18 Such offers 
often lack qualified genetic counseling,19 which is essential 
for an informed decision regarding WGS testing. Qualified 
genetic counseling supports complex decision-making with 
regard to the following questions: Do the results affect my 
family members? Who has access to my genetic information? 
What is the potential for genetic discrimination (eg, in terms 
of insurability)? Am I willing to pay for the testing out-off-
pocket? Do I want to know the probability of developing 
all diseases or only the probability of developing treatable 
diseases? How sensitive is the test?
For the purpose of identifying relevant attributes of online 
WGS testing, we conducted a discrete choice experiment 
(DCE) to evaluate the preferences of the general popula-
tion. We investigated the people’s preference estimates 
without prior qualified genetic counseling. We analyzed 1) 
the preferences of our study population and subgroup effects 
(eg, sociographic characteristics, genetic predisposition, 
and desire for children), 2) the willingness to pay of these 
subgroups, and 3) factors influencing the willingness to take 
part in WGS tests.
Methods
DCE
We conducted a DCE to measure the preferences for WGS 
testing. A DCE is a de-compositional approach to the mea-
surement of stated preferences. Participants have to choose 
between hypothetical alternatives. One alternative consists 
of several attributes with varying levels.20 The attributes are 
characteristics of the alternatives that are specified by their 
levels for each alternative.
Attributes and levels
First, we conducted a literature search to achieve a compre-
hensive overview of the available attributes of WGS. How-
ever, no literature focusing on preferences for WGS attributes 
could be identified. Hence, we adopted relevant attributes 
from actual discussions and literature focused on genetic 
analysis. The final relevant attributes for the DCE were “test 
accuracy”,21 “test cost”,22 report of results23–25 (divided into 
“identified diseases” and “probability of occurrence”), and 
“access to data”.26 The range of levels was also determined 
by specific discussion points or based on the literature on 
the subject. Finally, attributes and levels were discussed with 
experts. To improve the validity and reliability of each item, 
a pretest of the questionnaire was conducted with 11 people. 
Table 1 illustrates the attributes and their corresponding lev-
els. The attributes and levels are explained using colloquial 
language and icons, and they were adjusted after the pretest.
Data collection and recruitment
People from the German general population aged ≥18 years 
were eligible to participate in the survey. It was an online 
survey via Facebook and Xing that was conducted from 
June to August 2016, as well as by direct (and random) 
approach of passersby with a paper–pencil questionnaire 
at the main railway station in the city of Hannover (north-
western  Germany). We used a simple random sampling 
strategy and did not select participants according to age and 
sociodemographic or economic status. We obtained study 
approval from the ethics committee of Hannover Medical 
School (Re No 3325-20016) prior to the start of the survey. 
To take part in the study, participants had to give written 
informed consent.
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Questionnaire
The final questionnaire consisted of three sections. The first 
part was the DCE choice sets. In total, the attributes and levels 
resulted in 34×41=324 possible combinations (four attributes 
with three levels and one attribute with four levels).20 To gen-
erate feasible choice sets of the DCE, a D-efficient fractional 
factorial design (reduced design) was created using the R 
statistical program. The best D-efficiency occurred for 18 
choice sets. To avoid overstraining of the participants, we 
divided the 18 choice sets into two questionnaires (blocking). 
Therefore, participants answered nine DCE decisions with 
two alternatives (called Test 1 and Test 2) each. Additionally, 
we asked whether the participant would carry out the chosen 
test in reality (refer the example of the choice in Figure 1). 
The second part focused on sociodemographic questions, 
such as sex, age, education, occupation, monthly net income, 
and insurance company (statutory or private). The third part 
included questions about overall health status, prevention 
behavior, hereditary diseases, and desire for children.
Data analysis
Following survey completion, we cleaned the data set and 
determined descriptive statistics for the variables (median, 
standard deviation [SD], and percentages). We tested the 
potential independent variables for multicollinearity to reduce 
the bias of the results. In the multivariate analyses, we applied 
generalized linear mixed-effects models (GLMMs) and latent 
class mixed logit models (LCMLMs) to identify systematic 
or group differences for the participants’ WGS preferences. 
The choice of an alternative between two hypothetical WGS 
Table 1 Overview of attributes with the corresponding levels
Attribute Description in the questionnaire Level 1 Level 2 Level 3 Level 4 
Accuracy 
(sensitivity)
Test accuracy describes the proportion of persons with 
an identified genetic mutation that actually have this 
mutation 
For example, a level of 90% means that 90 of the 100 
people really have the risk to develop a certain disease. 
In contrast, in 10 of the 100 people, a disease risk is 
identified because of inaccuracy of the test, although they 
do not have this risk
You can choose between different tests with different 
accuracy values
90% 95% 99% 
Identified 
diseases
You can choose about the test results you want to be 
informed
You can choose the test results that you want to be 
informed about. You have the choice between reporting 
of all test results, only treatable diseases (preventive and 
therapeutic treatments), and serious hereditary diseases 
In case of serious hereditary diseases, it is assumed 
that these are inherited with a high probability and are 
characterized by a serious disease progression
All diseases Treatable disease Serious 
hereditary 
disease
Test costs A WGS is an innovative, diagnostic instrument and 
currently associated with high execution costs. You 
should decide how much money you are willing to pay 
for this comprehensive genetic analysis
€500 €1,000 
 
€1,500 
Probability of 
occurrence
The results of a WGS determine the risk of being 
affected by a specific disease. A genetic mutation enables 
statements about the probability of developing different 
diseases.  
You can decide which probability of developing a disease 
you want to be informed
10% 40% 70%
Access to data WGS is associated with a large amount of personal data. 
You can decide who can get access to your test results in 
addition to you and your treating physician
For example, you can make your genetic data accessible 
to researchers and thus contribute to medical research
No one else
 
Insurer Researcher
 
Insurer and 
researcher 
Abbreviation: WGS, whole genome sequencing.
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tests (choice) was used as the dependent variable, whereas 
the attributes and levels were the independent variables in 
all models. In addition, personal characteristics of the par-
ticipants were used as independent variables, mixed effects 
(taking into account that personal characteristics influence the 
response behavior and therefore including subgroup specific 
“baseline” values [random intercept] or slope adjustments 
[random slope] for some of the independent variables in 
addition to the fixed effects), or class-membership effects (for 
LCMLM). We calculated the average marginal willingness to 
pay (mWTP) for each attribute by dividing the coefficients 
for the other attributes by the coefficient of the cost attribute 
(test costs). Therefore, we used the attributes as metric inde-
pendent variables in conditional logit models and conducted 
the mWTP analysis separately for the different classes from 
the LCMLM analyses. Coefficients of attributes above zero 
were favored, and negative coefficients were disfavored. The 
95% confidence intervals (CIs) are based on the Krinsky and 
Robb27 method.
We calculated the GLMM for participants willing to 
participate in reality (potential users) and the full sample 
separately, so that any differences between these two groups 
could be identified. In the GLMM, we used the set ID 
(identification number of the choice set) as a mixed effect to 
Figure 1 Example of a choice set.
Notes: Explanation for the example choice set: The participant could choose between test 1 and test 2. Test 1 is characterized by a lower test accuracy (95%), with the 
reporting of treatable results at a 10% probability of disease occurrence as well as higher cost (€1,500), and the access for insurer. Test 2 is designed with a higher accuracy 
(99%), with the reporting of serious hereditary diseases at a higher probability of disease occurrence (70%) and at lower cost (€500). Furthermore, in test 2, no one else had 
access to the test results. The participant has to trade-off between a test accuracy of 95 and 99%, the costs of €1,500 and €500, and so on.
Test accuracy
Test 1
95%
Treatable diseases
€ 1,500
10%
Insurer No one else
70%
€ 500
Serious hereditary diseases
99%
Test 2
Identified diseases
Test costs
Probability of occurrence
Access to data
How many people are to be identified who
actually have the disease risk?
Which test results you want to be
informed?
How much money you are willing to pay for this
comprehensive genetic analysis.
Which probability of developing potential
diseases you want to be informed?
Who can get access to your test results in
addition to you and your treating physician?
Which test would you choose?
Test 1
Test 2
Yes
No
Would you carrry out the chosen test under the given condition also in reality?
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inform the model about which of the alternatives formed a 
set. Finally, we investigated the factors influencing the will-
ingness to participate in genetic testing in reality. Therefore, 
we applied another GLMM based on the variable “real” as a 
dependent variable. The random effect used in this model was 
the person identifier (PersonID) to enable us to investigate 
influencing participants’ characteristics and test character-
istics based on the decision. An overview of used variables 
is provided in Table S1.
We tested different independent variables and mixed 
effects in the models (Table S2) and chose the model with 
the best fit for data based on Akaike and Bayesian informa-
tion criteria. All analyses were conducted with R statistics 
3.1.2 and the packages “lme4” (for GLMM), “lcmm” (for 
LCMLM), and “support.CEs” (for mWTP analyses).
Results
Descriptive statistics
In total, 323 people participated in the study and 301 people 
could be included in the DCE analyses. All sample charac-
teristics are provided in Table 2. Twenty-two participants had 
to be excluded because of missing data for all DCE tasks or 
an age of <18 years. The sample consisted of 69% women, 
and the median age was 28 years. The educational level 
was higher compared to that of the general population of 
Germany,28 but the average amount of income was  similar.29 
Both facts indicated that the proportion of students was higher 
compared to the general population. The majority (56%) of 
the participants were in good health.
In a second step, we prepared the data for the multivari-
ate analyses. We found strong correlations between age and 
employment status, having children and employment status, 
and age and desire to have a child (refer correlation plot in 
Figure S1). Therefore, we adapted the models for these cor-
relations due to not using both correlating variables in one 
model or due to including interaction effects between the 
correlating variables.
Subgroup-specific preferences for WGS 
tests
In the LCMLM, we identified two classes that differed in 
regard to their preferences for genetic testing (Figure 2 and 
Table S3). Class 1 comprised 46.13% (n=137) of the sample. 
The only significant differentiator between the people in the 
two classes was their sex. The proportion of women was 
significantly lower in class 1 than in class 2 (refer the table in 
Figure 2). The educational level, health status, and income are 
relevant for the class membership but did not show significant 
differences between the classes.
In class 1, a higher proportion of men compared to 
the other classes strongly preferred the restricted “access 
to data only for themselves” (b
class 1,access no
=0.76, reference 
level) and disfavored the “access to data for insurer” the 
most (b
class 1,access ins
=-0.48, P < 0.001). They also disfavored 
any “test costs” where €1,000 had a utility weight of ~0 but 
was not significant. Class 1 preferred “serious hereditary 
diseases identified” and a “10% probability of occurrence” 
(b
class 1, ser.d
=0.16, β
class 1, 10% occ
=0.16, P<0.001) (Figure 2). In 
contrast, class 2 disfavored “10% and 70% probability of 
occurrence” but also preferred “serious hereditary diseases 
Table 2 Sample description
Variable Occurrence in  
the sample
Participants (number)
With at least one valid DCE task
323
301
Sex (% women) 69
Age in years (median, SD) 28 (13.86)
Own children (% having at least one child) 41
Desire to have children (%)
Yes
No
Unsure
50
39
11
Highest level of education (%)
No graduation
Primary school
Secondary school
High school
University
1
6
34
24
34
Income (%)
No own income (€)
<1,000
1,000–<2,000
2,000–<3,000
3,000–<4,000
≥4,000
16
27
29
17
6
4
Participation in screening program (%)
Never
Every 10 years
Every 5 years
Every 2 years
1–2 times a year
51
3
9
21
15
Subjective health status (%)
Very bad
Bad
Medium
Good
Very good
0
4
24
56
16
Hereditary diseases in the family (% yes) 20
Afraid of hereditary diseases (% yes) 21
Note: Median: average.
Abbreviations: DCE, discrete choice experiment; SD, standard deviation.
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identified”. Indeed, the highest preferences occurred for 
access to data only for themselves and “for researchers” 
(b
class 2, access no
=0.36, reference level; b
class 2, access res
=0.31, 
P<0.001). Class 2 also preferred “access to data only for 
insurer and researcher”. Class 2 disfavored “90% and 99% 
test accuracy” and showed a significant positive utility for 
“€1,000 test costs”.
To conclude, men emphasized the importance of access to 
data only for themselves and favored a test with 95% accuracy 
also for diseases with a low probability of occurrence. The 
class with a higher proportion of women favored instead a 
test that identifies serious hereditary diseases, where test costs 
on the intermediate level arise, and that enables data access 
for themselves or researchers.
In addition, we calculated the mWTP for each attri-
bute, separated for class 1 and class 2 from the LCMLM 
(Table 3). The mWTP showed different starting points 
for class 1 and class 2 models (intercept
class 1
: €786.3 and 
intercept
class 2
: €-1,931.3). From this, it can be concluded 
that people in class 2 were willing to pay less money for 
genetic testing than those in class 1. Furthermore, class 
2 was willing to pay on average €740 for an increase of 
one unit (90%–95% or 95%–99%) in test accuracy (CI: 
€489.5; €1,218.2) and on average €1,500 (€1,071.5; 
€2,435.5) for diseases with higher probability of occur-
rence. In contrast, the mWTP was negative for the iden-
tified diseases (€-303.7 [€-560.2; €-127.1]) and the 
access to data (€-383.8 [€-645.3; €-228.7]). Therefore, 
people were willing to receive monetary compensation for 
identifying only treatable and hereditary diseases. Class 
1 was willing to pay on average less for a higher test 
accuracy, although the monetary value was still positive 
(intercept €786–128=€658 for a change from 90% to 
95%). In addition, this class showed negatively associ-
ated mWTP for identified diseases (€-164.6 [€-289.7; 
€-45.1]) and the probability of occurrence (€-502.3 
[€-707.4; €-356.8]). In contrast, class 1 was willing to 
pay ~€723 [€561.2; €967.9] more for less access to data.
Figure 2 LCMLM for preferences concerning genetic testing – attribute effects.
Note: *Significant values (P<0.05).
Abbreviations: EDL, educational level; HSn, health status (numeric); INCn, income (numeric); LCMLM, latent class mixed logit model.
Test accuracy
Class-membership effects
Coefficient
Intercept
Sex (ref = male)
Educational level
Health status
Income
Class 1 (ref = class 2)
Standard error P-value
1.93 0.94
0.29
0.14
0.19
0.11
0.04
0.03
0.54
0.14
0.40
–0.64
0.09
–0.28
–0.09
Graph adjusted for further effects: mixture = –Att_TA + Att_DIS + Att_TC + Att_ACC, random = ~seti, subject= “personID”, classmb= ~sex + EDL + INCn + HSn
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Analysis of participation in genetic testing
We estimated GLMMs (full sample, potential users) to 
identify the preferences for genetic testing. The most 
important attribute level for genetic testing for both sub-
groups was the “identification of severe hereditary diseases” 
(Table S4). Therefore, this attribute level is more important 
for potential users (b
user,ser.dis.
=0.88) than for the full sample 
(b
full,ser.dis.
=0.49). However, the most disfavored attribute 
level for both subgroups was access to data for insurer 
(b
full,insur
=-0.81, b
user,insur.
=-0.64, both P<0.001). It is strik-
ing that for test accuracy, identified diseases, test costs, and 
probability of occurrence, the intermediate level gained 
the highest utility weight in both subgroups. Although the 
preferences were similar between the subgroups, the full 
sample preferred “95% test accuracy”, €1,000 test costs, 
and “access to data for researchers” more strongly than the 
potential user subgroup.
In the last step, we investigated the factors that influenced 
the willingness of respondents to participate in genetic test-
ing in reality or if they just preferred the chosen alternative 
hypothetically. The GLMM showed that from the attributes, 
only test accuracy and access to data were relevant for the 
decision (Table 4). All costs reduced the willingness to 
participate in genetic testing; however, €500 was the least 
disfavored level (b€
500
=-0.024). In addition, people were 
more willing to participate when the access to data would 
be denied to insurers and researchers. In contrast to previous 
models, the decision to participate in reality was positively 
influenced by access to data for researchers and not “only for 
themselves”. Educational level showed a negative association 
to the participation in genetic testing. In addition, people who 
would participate in screenings if the social or private health 
insurance (SHI) subsidized it were more willing to participate 
in genetic testing (b
scr subs SHI
=1.86, P<0.001). “Employment 
status”, “income”, and “fear of genetic diseases” did not show 
significant results, although the direction of the coefficients 
was as expected.
Main findings
The most preferred test for the overall sample was character-
ized by the following aspects: 1) the test accuracy of 95%, 
2) report of severe hereditary diseases, 3) the test cost of 
€1,000, 4) report of results for diseases with a probability 
of occurrence from 40%, and (5) access to genome data for 
researcher but not for insurers (Table S4). Except for “access 
to genome data”, all intermediate levels achieved the high-
est utility weights in both the full sample and the sample of 
potential users (Table S3).
Discussion
In this study, the preferences for WGS testing without quali-
fied genetic counseling were assessed.
The test accuracy of 95%, especially sensitivity in this 
case, was the most favored level of this attribute. This may 
show that the participants did not understand (or only partly 
understood) the underlying concept of test sensitivity and 
Table 3 Marginal willingness of classes to pay for test attributes
Attribute Levels Class 1: mWTP in € (95% CI) Class 2: mWTP in € (95% CI)
Intercept 786.3 (308.5; 1,233.9) –1,931.3 (–3,935.2; –905.2)
Test accuracy 90%–99% –127.6 (–258.7; –17.9) 737.8 (489.5; 1,218.2)
Identified diseases All, treatable, hereditary –164.6 (–289.7; –45.1) –303.7 (–560.2; –127.1)
Probability of occurrence 10%–70% –502.3 (–707.4; –356.8) 1,514.5 (1,071.5; 2,435.5)
Access to data Insurer, researcher and insurer, researcher,  
no one else
722.9 (561.2; 967.9) –383.8 (–645.3; –228.7)
Note: Class 1: higher proportion of men; Class 2: higher proportion of women.
Abbreviations: CI, confidence interval; mWTP, marginal willingness to pay.
Table 4 GLMM fixed-effects results for participation in genetic 
testing
Variables Levels Coefficient SE P-value
Test costs €1,500 –0.261 0.100 0.009
€1,000 –0.237 0.090 0.009
€500 (ref) –0.024
Probability 
of 
occurrence
10% –0.089 0.101 0.375
40% –0.012 0.094 0.897
70% (ref) –0.077
Access to 
data
Insurer and researcher –0.275 0.118 0.019
Researcher 0.097 0.106 0.358
Insurer –0.349 0.134 0.009
No one else (ref) –0.024
Educational level –0.693 0.263 0.008
Employment status –0.858 0.541 0.113
Income 0.338 0.226 0.134
Screening utilization: subsidy by SHI 1.857 0.465 0.000
Afraid of genetic diseases 0.975 0.564 0.084
Notes: Intercept coefficient 1.409; SE 1.231; P 0.252 and random intercept 
PersonID variance 9.765; standard deviation 3.125.
Abbreviations: GLMM, generalized linear mixed-effects model; SE, standard error; 
SHI, social or private health insurance.
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false-positive results. We expected that the most preferred 
level would be 99% test accuracy. False-positive findings lead 
to anxiety and uncertainty for the tested person as well as for 
their families.30 This in turn may require an additional diag-
nostic clarification or leads to an increased treatment demand 
(eg, psychological counseling). Finally, false-positive results 
could cause an unnecessary rising cost for the statutory health 
insurance. Otherwise, the participants may understand the 
underlying concept but accept the uncertainties to receive 
other advantages, eg, lower test costs.
The amount of reported results was also an important 
aspect for the decision regarding WGS tests. This aspect is 
represented by the probability of occurrence (in this experi-
ment 10%, 40%, or 70%) as well as by the kinds of reported 
diseases (all disease dispositions, only treatable [potential] 
disorders, or only severe hereditary diseases). The majority of 
the participants preferred the reporting of serious hereditary 
diseases. “All disease dispositions” were not attributed with 
the highest utility score; this may be in accordance with the 
aspects of efficiency and evidence. Technological progress 
and genetic research enables the detection of a majority of 
diverse gene variants. However, many identified genetic varia-
tions are not assigned to phenotypes, or the interaction of the 
specific gene variants is actually unknown.31 This may change 
in the future because of further genomic research, especially 
through GWAS. So far, there are no therapy options for most 
of the identified gene variants and diseases. However, the par-
ticipants preferred 40% “probability of disease occurrence”. 
This may indicate that the general population cannot assess 
the absolute risks for developing a disease without counseling 
or the influence on disease development caused by lifestyle 
changes (e.g., sports, nutrition), or that prevention measures 
may be assessed as a more important and changeable fac-
tor. These preferences could occur because of unawareness 
about genetic risk factors of the participants, due to lack 
of qualified counseling, or because of their risk aversion. 
Another limiting factor could be the three given levels of 
the probabilities. Since the participants were forced to prefer 
one of the given levels, the range of the outcomes could also 
be limited. However, the first explanation is emphasized by 
the negative effect of educational level on the willingness to 
participate (Table 4).
Cost reduced the willingness to participate in the WGS 
testing in reality (Table 4). Accordingly, subsidies by SHI for 
WGS testing showed a positive effect on the willingness to 
participate in testing. However, €1,000 received the highest 
approval in the LCMLM. This may be due to the association 
between the rising costs and the quality or the knowledge of 
the “$1,000 genome”, which means the often discussed cost 
reduction of a WGS to $1,000 in recent years.32 Otherwise, 
health care systems with little or no out-of-pocket payments 
for prevention measures could influence the importance of 
cost attributes for the participants’ decisions. However, the 
participants’ income did not influence the class membership 
and preferences. In the mWTP analyses, we found that the 
willingness to pay in class 2 (higher proportion of women) 
was highest for the attribute of probability of disease occur-
rence, whereas the highest mWTP occurred for access to 
data in class 1 (higher proportion of men). Furthermore, the 
direction of mWTP for several attributes was different for 
these two classes. Thus, the mWTP seemed highly dependent 
on the examined subgroup. The formation of class 1 (higher 
proportion of women) and class 2 (higher proportion of men) 
highlights the differences between males and females. While 
males preferred restricted access to data only for themselves, 
females wanted to make their genetic data accessible to 
research. Secrecy of personal data is seemingly very impor-
tant to men, while women may want to contribute to genetic 
research. Further differences arose in reporting of results. 
Females and males preferred a reporting of results at a 40% 
and 10% probability of disease occurrence, respectively. Fear 
of a variety of predictive findings (women) or the desire to 
know almost all dispositions (men) may be possible explana-
tions for this finding.
In the future, cost reductions will be expected because of 
the focus on genetic analyses of specific variants. Currently, 
for example, in the case of presumed heredity of breast 
cancer, the first-degree-relative risk patients are often tested 
only for the specific variant (eg, BRCA I and BRCA II).33 
Further improvements in WGS testing could contribute to 
it becoming the favorable alternative compared to panel or 
single gene sequencing.
Potential users as well as the full sample rejected the 
access of test results to insurance agencies. Fear of genetic 
discrimination, eg, in terms of insurability or direct and/or 
indirect risk selection, seems to be particularly substantial.34 
However, due to a ban on discrimination and the obligation to 
contact, this risk is excluded in the statutory health insurance 
in Germany. In other insurance areas (private health insur-
ance, life insurance, and occupational disability insurance), 
these data could have a stronger influence on insurability 
and insurance premium, which may lead to uncertainty and 
anxiety. Despite the strong regulations, anxiety and fear of 
data misuse seem to be the sensitive issues. Further research 
is needed in these areas. However, the DCE results suggested 
that potential users preferred to give researchers access to 
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genetic data. Genetic research is a dynamic field, and com-
prehensive genetic databases are the prerequisite for research. 
The fear of disease as well as the interest in research and 
further medical developments may be essential drivers for 
the preferences in this study. Thus, people have the opportu-
nity to contribute to medical research. With regard to large 
genome sequencing projects, such as the 100,000 Genomes 
Project (UK),35 the Saudi Human Genome Program (Saudi 
Arabia),36 and the GoNL (the Netherlands),37 the German 
population also showed interest. The reporting of test results 
could be restricted or completely rejected in qualified WGS 
testing, eg, to findings of the ACMG-positive list (Recom-
mendations for Reporting of Incidental Findings in Clinical 
Exome and Genome Sequencing).38 Basically, the decision 
for or against a WGS test in reality depended on the specific 
design (characteristics level) in 53.26% of the cases. While 
26% of the participants rejected a WGS test independent of 
specific levels, 20.74% of the participants would execute a 
WGS test independent of the test characteristics in reality.
The possibilities for using genetic testing results in 
diagnosis and therapy have steadily increased. Therefore, 
the WGS offers an opportunity to detect a majority of dis-
orders, especially using a predictive approach. However, 
in Germany, the costs of genetic analyses for patients at 
risk (eg, first-degree relatives of breast cancer patients) are 
covered by a variety of health insurance plans, whereas 
predictive genetic testing for nonpredisposed people is an 
out-of-pocket expense. Therefore, comprehensive genetic 
direct-to-consumer (DTC) analysis via the Internet seems 
to be a less expensive alternative,18 although DTC options 
often lack qualified genetic counseling.19 As we can see 
from our survey, not all stated preferences are consistent 
with the qualified recommendations. Therefore, our study 
results emphasize the importance of genetic counseling. In 
Germany, human genetic counseling for predictive analysis 
is obligatory in accordance with the § 10 German Act of 
Gene Diagnostics (GenDG). Two main results underline the 
claim for genetic counseling: 1) the chosen test accuracy of 
95% and the associated higher risk of false-positive results 
(in contrast to a test accuracy of 99%) and 2) the selected 
probability of disease occurrence at a level of 40% for the 
reporting of results. For a majority of disease dispositions, 
there are no treatment options at the moment. Therefore, 
people may be confronted with information on a large num-
ber of potential diseases, which will lead to anxiety. Genetic 
counseling may help to understand what penetrance really 
means and which consequences of a finding with a prob-
ability of 40% occurrence will arise. However, a possible 
explanation for these preferences might be that people assume 
that their doctors will receive the WGS test results and help 
them to understand and interpret their results. The attribute 
access to data is characterized by the possibility of access 
to the genetic information by the treating physician. Due 
to medical secrecy, we excluded the risk and the anxiety of 
data misuse. A person can decide if they want to share these 
genetic results with the treating physician, which would be 
beneficial for understanding. Prior genetic consultations may 
have an influence on the general decision for the execution 
and the scope of reporting of the results. However, in the pres-
ent study, we excluded such a prior consultation to explore 
the preferences without a qualified genetic counseling (which 
is partially lacking in a genetic DTC analysis).
One limitation of this experiment is the hypothetical 
character. The revealed preferences may lead to another 
distribution of utility weights. Furthermore, the importance 
of test specificity was neglected. The difference between 
sensitivity and specificity is difficult for the general popula-
tion to understand, and therefore, we focused on test sensi-
tivity in the DCE. The representativeness of the sample is 
also limited. The sample of a primarily online acquisition is 
mainly characterized by younger and Internet-savvy people. 
However, we assumed that the topic is most relevant for this 
group. In the direct approach, we only recruited a small 
number of participants (n<10), so we could exclude a selec-
tion bias. Although we included the relevant test attributes 
and important sociodemographic characteristics of the study 
population, further factors (eg, risk aversion) could influence 
the preferences. The calculations of mWTP should be consid-
ered with caution. We treated the level differences as linear, 
although this is not intuitive. For example, we assumed that 
the difference from 90% test accuracy to 95% had the same 
effect as a change from 95% to 99% in mWTP. However, we 
needed to assume linear effects for calculating the average 
willingness to pay and show differences between the classes. 
At the time of our study, there was a lack of literature describ-
ing the levels used for the attributes. Therefore, we considered 
the available literature and current discussion to derive the 
characteristics of the attributes. These data were discussed 
and approved by experts. Having a published qualitative 
study available would have led to a higher objectification of 
attribute and level selection. However, due to the short dura-
tion of the study, we had to forgo this possibility. In order to 
assess the relevance of the test conditions for nontest-savvy 
participants, an integration of an opt-out option was omit-
ted. The study can be considered a feasibility study based on 
the number of participants. To extrapolate the results to the 
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whole country, the number of participants needs to be larger 
and nationally representative.
This study reports on the interest and preferences for 
WGS testing among Germans. Our study sample from the 
general population of Germany was aware of the importance 
of WGS results, and they preferred to make their data acces-
sible for researchers but not for insurers because of possible 
discrimination. A positive attitude toward population-wide 
screening projects could therefore be assumed if data privacy 
is assured and the costs do not exceed €1,000. In general, 
the decision for or against a WGS is complex and could have 
far-reaching consequences. Hence, this decision should be a 
result of an informed consent process, where the attributes 
and consequences of a WGS are clarified.
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Supplementary materials
Table S1 Overview of used variables
Topics Variable Meaning Explanation Characteristics Type
D
C
E-
sp
ec
ifi
c 
va
ri
ab
le
s
Questionnaire
Set
Seti Questionnaire combined with set
Alternative 1
2
Choice 0: no
1: yes
Realn Real decision (numeric) Would you also choose the chosen 
alternative in reality?
0: no
1: yes
Numeric
A
tt
ri
bu
te
s
Att_TA Test accuracy Test accuracy 1: 90%
2: 95%
3: 99%
Att_DIS Identified diseases Test results 3: all
2: treatable diseases
1: serious hereditary disease
Att_TC Test costs Test costs 3: €1,500
2: €1,000
1: €500
Att_PROB Probability of occurrence Probability of occurrence of 
disease
1: 10%
2: 40%
3: 70%
Att_ACC
Access to data Access to data 4: insurer and researcher
3: researcher
2: insurer
1: no one else
So
ci
od
em
og
ra
ph
ic
 a
sp
ec
ts
PersonID Person identifier
Sex Sex 1: male
2: female
Binary
Age Age Numeric
EDL EDL Highest level of education 0: no graduation
1: primary school
2: secondary school
3: high school
4: university 
Numeric
ES ES 0: nonemployed
1: in training/student
2: employed/self-employed
Numeric
INCn INCn 0: no own income
1: <€1,000
2: €1,000–<€2,000
3: €2,000–<€3,000
4: €3,000–<€4,000
5: ³€4,000
Numeric
H
ea
lth
 in
su
ra
nc
e 
an
d 
 
ut
ili
za
tio
n 
of
 s
cr
ee
ni
ng
SHI Insurance 1: statutory
2: private
Binary
PSC PSC program 1: 1–2 times the year
2: every 2 years
3: every 5 years
4: every 10 years
5: never
Numeric
PSChin PSC program at full-cost 
coverage by health insurance
0: no
1: yes
Numeric
PSCshare_r PSC if health insurance pays 
a share
Recoded variable if Kostzu =1 or 
Kostal =1 then Kostzu_r =1
0: no
1: yes
Binary
(Continued)
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Topics Variable Meaning Explanation Characteristics Type
PSCsharen PSC if health insurance pays a 
share (numeric)
0: no
1: yes
Numeric
PSCpocketn PSC on own payment 
(numeric)
0: no
1: yes
Numeric
H
ea
lth
 s
ta
tu
s 
an
d 
di
se
as
es
HSn Subjective HSn 1: very bad
2: bad
3: medium
4: good
5: very good
Numeric
FHD Known FHD 0: no
1: yes
Binary
FHDfree Open questions to hereditary 
diseases in the family
Free text Free text
CHIn CHIn 0: no
1: yes
Binary
DCHIn DCHIn 0: no
1: I do not know
2: yes
Numeric
AFHD AFHD 0: no
1: yes
Numeric
AFHDfree Fear of which hereditary 
disease
Free text Free text
Abbreviations: AFHD, afraid of hereditary disease; CHIn, children (numeric); DCHIn, desire to have children (numeric); FHD, family hereditary disease; EDL, educational 
level; ES, employment status; HSn, health status (numeric); INCn, income (numeric); PSC, participation in screening; SHI, social or private health insurance.
Table S2 Overview of included independent variables used in GLMM and LCMLM
Model Dependent 
variable
Independent variables  
tested
Mixed effects Lean model
GLMM (for both 
participants and 
full-sample)
Choice Att_TA + Att_DIS + Att_TC + 
Att_PROB + Att_ACC, ES × EDL, KF, 
AFHD, CHI, DCHI, SE, HSn, PSC
PersonID, serial, Set, Seti, age, 
sex, EDL, ES
Wahl ~ Att_TA + Att_DIS + 
Att_TC + Att_PROB + Att_ACC 
+ ES × EDL + (1|Seti)
LCMLM Choice Att_TA + Att_DIS + Att_TC + Att_
PROB + Att_ACC
PersonID, Att_TA + Att_DIS 
+ Att_TC + Att_PROB + 
Att_ACC, classmb: age, sex, SHI, 
ES, EDL, INCn, HSn, PSC, KF, 
AFHD, CHI, DCHI, Kostzu_r, 
EDL × HSn
Wahl ~ Att_TA + Att_DIS + 
Att_TC + Att_PROB + Att_ACC, 
random = ~ Seti, subject = 
“PersonID”, mixture = ~ Att_TA 
+ Att_DIS + Att_TC + Att_PROB 
+ Att_ACC, classmb = ~ sex + 
EDL + INCn + HSn, ng =2, data = 
Daten, link = “linear”
GLMM real Real Datentn$Att_TA + Datentn$Att_DIS 
+ Datentn$Att_TC + Datentn$Att_
PROB + Datentn$Att_ACC
PersonID Datentn$sex + 
Datentn$age, +PSCpocketn + 
SHI, EDL+ES + INCn + PSC + 
Kostzu_r + Khf + CHIn + HSn + 
DCHIn + PSC, AFHD
Real ~ Att_TC + Att_PROB + 
Att_ACC + EDL + ES + INCn + 
Kostzu_r + AFHD (1|PersonID)
Abbreviations: AFHD, afraid of hereditary disease; CHI, children; CHIn, CHI (numeric); DCHIn, desire to have children; DCHIn, DCHI (numeric); EDL, educational 
level; ES, employment status; GLMM, generalized linear mixed-effects model; HSn, health status (numeric); INCn, income (numeric); KL, known familar hereditary diseases; 
LCMLM, latent class mixed logit model; PSC, participation in screening; SHI, social or private health insurance.
Table S1 (Continued)
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Table S3 Latent class mixed logit model results – attribute effects
Attributes and levels Class 1 (higher proportion of men) Class 2 (higher proportion of woman)
b coefficient SE P-value b coefficient SE P-value
Test accuracy
90% –0.002 0.04244 0.962 –0.234 0.03229 0.000
95% 0.079 0.03596 0.027 0.015 0.03102 0.634
99% (ref) –0.081 –0.248
Identified diseases
All diseases 0.082 0.0405 0.043 0.137 0.03581 0.000
Treatable diseases –0.078 0.03621 0.030 –0.088 0.03373 0.009
Serious hereditary disease (ref) 0.160 0.225
Test costs
€1,500 –0.216 0.03467 0.000 –0.151 0.03073 0.000
€1,000 –0.016 0.03283 0.620 0.108 0.03043 0.000
€500 (ref) –0.200 –0.259
Probability of occurrence
10% 0.158 0.03623 0.000 –0.398 0.0341 0.000
40% 0.075 0.03431 0.029 0.007 0.03158 0.834
70% (ref) 0.083 –0.404
Access to data
Insurer and researcher –0.200 0.04125 0.000 0.142 0.03933 0.000
Researcher 0.282 0.03912 0.000 0.314 0.03644 0.000
Insurer –0.478 0.04563 0.000 –0.043 0.03765 0.258
No one else (ref) 0.760 0.357
Intercept
0 NA NA –0.01679 0.0276 0.54311
Notes: Adjusted for class-membership effects, sex, educational level, and income; subject, “PersonID”.
Abbreviations: SE, standard error; NA, not applicable.
Table S4 Results from the generalized linear mixed-effects model
Topics Variables Levels Full sample Potential users
b coefficient SE P-value b coefficient SE P-value
A
tt
ri
bu
te
s
Test 
accuracy
90% –0.330 0.050 0.000 –0.251 0.072 0.000
95% 0.120 0.051 0.020 0.028 0.075 0.709
99% (ref) –0.450 –0.279
Identified 
diseases
All diseases 0.228 0.049 0.000 0.496 0.071 0.000
Treatable diseases –0.259 0.050 0.000 –0.386 0.073 0.000
Serious hereditary disease (ref) 0.487 0.882
Test costs €1,500 –0.515 0.051 0.000 –0.497 0.073 0.000
€1,000 0.067 0.046 0.148 –0.013 0.067 0.842
€500 (ref) –0.582 –0.483
Probability of 
occurrence
10% –0.411 0.051 0.000 –0.373 0.073 0.000
40% 0.100 0.050 0.043 0.092 0.072 0.199
70% (ref) –0.511 –0.466
Access to 
data
Insurer and researcher –0.011 0.062 0.860 –0.033 0.089 0.709
Researcher 0.755 0.065 0.000 0.554 0.092 0.000
Insurer –0.812 0.067 0.000 –0.636 0.102 0.000
No one else (ref) 0.046 0.049
Pe
rs
on
-
sp
ec
ifi
c 
da
ta
Employment 0.000 0.131 1.000 –0.007 0.342 0.983
Educational level 0.000 0.076 1.000 –0.006 0.194 0.975
Employment × educational level 0.000 0.045 1.000 0.106 0.981
Intercept 0.007 0.258 0.978 0.020 0.654 0.975
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Preferences for whole genome sequencing tests
Figure S1 Correlation plot of independent variables.
Notes: The significance level was a P-value of 0.05. X: not significant correlations. Dark blue indicates highly positive correlations. Dark red indicates highly negative 
correlations. Larger circles indicate higher correlations. PSCshare_r, PSC if health insurance pays a share.
Abbreviations: AFHD, afraid of hereditary disease; CHIn, children (numeric); DCHIn, desire to have children (numeric); EDL, educational level; ES, employment status; 
FHD, family hereditary disease; HSn, health status (numeric); INCn, income (numeric); PSC, participation in screening; SHI, social or private health insurance.
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